Ignite Creation Date:
2024-05-06 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 12:50 PM
Study NCT ID:
NCT03613727
Status:
COMPLETED
Last Update Posted:
2023-11-07
First Post:
2018-07-27
Brief Title:
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
Sponsor:
Virginia Commonwealth University
Organization:
Virginia Commonwealth University
Study Overview
Official Title:
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase 2 trial studies the effect of intravenous IV vitamin C repletion after myeloablative allogeneic stem cell transplant
Detailed Description:
Vitamin C is a nutritional supplement that can help fight inflammation Most patients who have a stem cell transplant have lower than normal levels of vitamin C in their blood Patients will receive intravenous Vitamin C the day after transplant for two weeks followed by oral vitamin C until six months after transplant The effect of the Vitamin C on non-relapse mortality NRM time to engraftment rate of acute graft-versus-host disease and to characterize the safety and tolerability of the vitamin C regimen
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2018-01502 | OTHER | NCI CTRP | None |